Naples prognostic score: a novel predictor of survival in patients with HER2-positive breast cancer

被引:12
作者
Chen, Yuye [1 ]
Guan, Zheming [3 ]
Shen, Guo [2 ]
机构
[1] Zhuji Peoples Hosp Zhejiang Prov, Dept Oncol, Shaoxing City 311800, Peoples R China
[2] Hangzhou Normal Univ, Affiliated Xiaoshan Hosp, Dept Gen Surg, Hangzhou 311202, Peoples R China
[3] Weifang Peoples Hosp, Weifang City 261000, Peoples R China
关键词
HER2-positive breast cancer; immunity; inflammation; Naples prognostic score; INFLAMMATION; TRASTUZUMAB; NEUTROPHILS; RECEPTOR; GRADE; CELLS; RATIO;
D O I
10.2217/fon-2022-0212
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plain language summary Breast cancer is one of the most frequent cancers in females and the second leading cause of death among women worldwide. HER2-positive breast cancer has the characteristics of rapid growth, high risk of relapse and cancer migration and spreading. The predictive significance of the Naples prognostic score (NPS) in HER2-positive breast cancer is unknown. We hypothesized that NPS may improve prediction of outcomes in HER2-positive patients. A statistical analysis was conducted. Our results revealed that NPS was an independent predictive factor of overall survival and disease-free survival in patients with HER2-positive breast cancer. Purpose: The predictive significance of the Naples prognostic score (NPS) in HER2-positive breast cancer is unclear. Hence we sought to evaluate the relationship between NPS and the clinical outcomes in HER2-positive breast cancer patients. Methods: This study retrospectively collected and analyzed data from 173 HER2-positive breast cancer patients between August 2004 and February 2014. The Cox regression model was applied in univariate and multivariate statistical analysis. Results: In multivariate analysis, increased NPS score correlated significantly with poor overall survival (p = 0.001) and disease-free survival (p < 0.001). Conclusion: Our findings may point to NPS being a novel and reliable prognostic score system with favorable predictive ability for HER2-positive breast cancer patients.
引用
收藏
页码:2655 / 2665
页数:11
相关论文
共 48 条
  • [1] Hematologic markers of distant metastases and poor prognosis in gynecological cancers
    Abu-Shawer, O.
    Abu-Shawer, M.
    Hirmas, N.
    Alhouri, A.
    Massad, A.
    Alsibai, B.
    Sultan, H.
    Hammo, H.
    Souleiman, M.
    Shebli, Y.
    Al-Hussaini, M.
    [J]. BMC CANCER, 2019, 19 (1)
  • [2] Systemic Inflammation, Nutritional Status and Tumor Immune Microenvironment Determine Outcome of Resected Non-Small Cell Lung Cancer
    Alifano, Marco
    Mansuet-Lupo, Audrey
    Lococo, Filippo
    Roche, Nicolas
    Bobbio, Antonio
    Canny, Emelyne
    Schussler, Olivier
    Dermine, Herve
    Regnard, Jean-Francois
    Burroni, Barbara
    Goc, Jeremy
    Biton, Jerome
    Ouakrim, Hanane
    Cremer, Isabelle
    Dieu-Nosjean, Marie-Caroline
    Damotte, Diane
    [J]. PLOS ONE, 2014, 9 (09):
  • [3] The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging
    Amin, Mahul B.
    Greene, Frederick L.
    Edge, Stephen B.
    Compton, Carolyn C.
    Gershenwald, Jeffrey E.
    Brookland, Robert K.
    Meyer, Laura
    Gress, Donna M.
    Byrd, David R.
    Winchester, David P.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) : 93 - 99
  • [4] Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells
    Blaisdell, Adam
    Crequer, Amandine
    Columbus, Devin
    Daikoku, Takiko
    Mittal, Khush
    Dey, Sudhansu K.
    Erlebacher, Adrian
    [J]. CANCER CELL, 2015, 28 (06) : 785 - 799
  • [6] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    Cameron, David
    Piccart-Gebhart, Martine J.
    Gelber, Richard D.
    Procter, Marion
    Goldhirsch, Aron
    de Azambuja, Evandro
    Castro, Gilberto, Jr.
    Untch, Michael
    Smith, Ian
    Gianni, Luca
    Baselga, Jose
    Al-Sakaff, Nedal
    Lauer, Sabine
    McFadden, Eleanor
    Leyland-Jones, Brian
    Bell, Richard
    Dowsett, Mitch
    Jackisch, Christian
    [J]. LANCET, 2017, 389 (10075) : 1195 - 1205
  • [7] Prognostic Nutritional Index (PNI) in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy as a Useful Prognostic Indicator
    Chen, Li
    Bai, Ping
    Kong, Xiangyi
    Huang, Shaolong
    Wang, Zhongzhao
    Wang, Xiangyu
    Fang, Yi
    Wang, Jing
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [8] Breast cancer statistics, 2019
    DeSantis, Carol E.
    Ma, Jiemin
    Gaudet, Mia M.
    Newman, Lisa A.
    Miller, Kimberly D.
    Sauer, Ann Goding
    Jemal, Ahmedin
    Siegel, Rebecca L.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (06) : 438 - 451
  • [9] Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
    Elinav, Eran
    Nowarski, Roni
    Thaiss, Christoph A.
    Hu, Bo
    Jin, Chengcheng
    Flavell, Richard A.
    [J]. NATURE REVIEWS CANCER, 2013, 13 (11) : 759 - 771
  • [10] Breast cancer in China
    Fan, Lei
    Strasser-Weippl, Kathrin
    Li, Jun-Jie
    St Louis, Jessica
    Finkelstein, Dianne M.
    Yu, Ke-Da
    Chen, Wan-Qing
    Shao, Zhi-Ming
    Goss, Paul E.
    [J]. LANCET ONCOLOGY, 2014, 15 (07) : E279 - E289